ciprofloxacin has been researched along with Primary Peritonitis in 107 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For the treatment of spontaneous bacterial peritonitis (SBP), cefotaxime, ceftriaxone, and ciprofloxacin were used as first-line agents." | 9.69 | Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP. ( Baik, SK; Han, KH; Heo, J; Heo, NY; Jung, YK; Kang, SH; Kim, BI; Kim, HS; Kim, MY; Kim, TH; Kim, YS; Park, JY; Park, SY; Seo, YS; Sohn, JH; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2023) |
| "For the prevention of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites, norfloxacin 400 mg per day is recommended as a standard regimen." | 9.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "To compare an intravenous-oral step-down schedule with ciprofloxacin (switch therapy) to intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis, and to evaluate the impact of terlipressin and albumin in the treatment of type 1 hepatorenal syndrome on mortality." | 9.12 | Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. ( Angeli, P; Antona, C; Brollo, L; Cillo, U; Craighero, R; Fasolato, S; Franchin, M; Gatta, A; Guarda, S; Merkel, C; Miola, E; Piccolo, F, 2006) |
| "The aim of this prospective double-blind study was to evaluate the value of long-term antibiotic prophylaxis using ciprofloxacin for the prevention of spontaneous bacterial peritonitis (SBP) in 60 cirrhotic patients with low ascitic fluid protein levels (< 15 g/L)." | 9.08 | Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. ( Bacq, Y; Bohn, B; Cordier, L; Franza, A; Fratte, S; Kitmacher, P; Nousbaum, JB; Paris, JC; Rolachon, A; Stahl, JP, 1995) |
| "The present study compared oral versus intraperitoneal (ip) ciprofloxacin (ciproxin) as primary treatment of bacterial peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD) in a randomized, prospective trial." | 9.07 | A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. ( Chan, CY; Cheng, IK; Cheng, SW; Cheung, WC; Lo, WK; Ritchie, CW; Wong, WT, 1993) |
| "In a prospective, randomized, controlled trial in 40 patients, intraperitoneal ciprofloxacin was shown to be as effective as the currently recommended regimen of intraperitoneal vancomycin and gentamicin for the treatment of CAPD peritonitis." | 9.06 | A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD). ( Fraise, AP; Friedland, JS; Iveson, TJ; Oliver, DO; Selkon, JB; Winearls, CG, 1990) |
| "This report describes a prospective, randomized comparison of oral ciprofloxacin and intraperitoneal vancomycin/netilmicin in the treatment of 50 consecutive episodes of CAPD peritonitis in 35 patients." | 9.06 | A comparison between oral ciprofloxacin and intraperitoneal vancomycin and netilmicin in CAPD peritonitis. ( Bint, AJ; George, JC; Orr, KE; Stansfield, E; Tapson, JS; Ward, MK, 1990) |
| "Ciprofloxacin was evaluated as single-agent therapy for the empirical treatment of patients presenting with CAPD peritonitis in an open, uncontrolled trial." | 9.06 | Intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD). ( Barton, I; King, A; Ludlam, HA; McMullin, C; Phillips, I; White, L, 1990) |
| "Fifty-one patients were included in a prospective, randomized comparison of oral ciprofloxacin and intraperitoneal vancomycin/gentamicin in the treatment of CAPD peritonitis." | 9.06 | A comparison between oral ciprofloxacin and intra-peritoneal vancomycin and gentamicin in the treatment of CAPD peritonitis. ( Barrett, A; Bennett-Jones, DN; Russell, GI, 1990) |
| "To estimate the efficacy of ciprofloxacin in the treatment of pelvic peritonitis, a pharmacokinetic study was conducted in four Japanese subjects." | 7.72 | Pharmacokinetics of single-dose intravenous ciprofloxacin in blood and ascites of patients with pelvic peritonitis. ( Mikamo, H; Ninomiya, M; Tamaya, T, 2003) |
| "We present the results of a protocol of empiric monotherapy of continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis with ciprofloxacin (CPX), with a special emphasis on the evolution of our results after seven years of continued use of this drug." | 7.69 | Treatment of CAPD-related peritonitis with ciprofloxacin: results after seven years. ( Bouza, P; García Falcón, T; López Vázquez, M; Pérez Fontán, M; Rodríguez-Carmona, A; Tresancos, C; Valdés, F, 1996) |
| "We present the long-term results of a protocol of empirical monotherapy of continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis with ciprofloxacin." | 7.68 | Treatment of peritonitis in CAPD with ciprofloxacin: long-term experience. ( Adeva, M; Fernández Rivera, C; García Falcón, T; Moncalián, J; Pérez Fontán, M; Rodríguez-Carmona, A; Rosales, M, 1993) |
| "Ciprofloxacin cannot be recommended for the treatment of intermittent peritoneal dialysis-related Gram-positive bacterial peritonitis." | 7.68 | Poor response to oral ciprofloxacin in the treatment of peritonitis in patients on intermittent peritoneal dialysis. ( Fong, IW; Johnson, MD; Waite, NM; Webster, NR, 1993) |
| "Ciprofloxacin at a dose of 25 mg/L of dialysate was administered intraperitoneally for five days as a single agent for the empirical treatment of CAPD peritonitis." | 7.68 | Low dose intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD). ( Dryden, MS; Phillips, I; Wing, AJ, 1991) |
| "Forty two patients with general peritonitis were treated with ciprofloxacin and combinations of various antimicrobial drugs." | 7.68 | [Ciprofloxacin and other antimicrobial drugs in the treatment of disseminated peritonitis]. ( Bush, V; Chugunov, AO; Gorskiĭ, VA; Korshumov, VM; Kriger, AG; Levanov, AV; Shurkalin, BK, 1992) |
| " The aim was to investigate the efficacy of long-term administration of ciprofloxacin to prevent SBP." | 6.73 | Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. ( Abecasis, R; Cartier, M; Dominguez, N; Fassio, E; Guevara, M; Landeira, C; Levi, D; Longo, C; Lucero, R; Miguez, C; Muñoz, A; Romero, G; Terg, R, 2008) |
| "Ciprofloxacin was given two hours after any phosphate binder or iron supplement." | 6.69 | Once-daily intraperitoneal cefazolin and oral ciprofloxacin as empiric therapy for the treatment of peritonitis. ( Finkelstein, F; Gorban-Brennan, N; Kliger, A; Troidle, L, 1999) |
| " The dosage was deduced from a pilot study and consisted of an intra-peritoneal loading dose during the first 24 hours." | 6.67 | Oral treatment of CAPD-peritonitis with ciprofloxacin. ( Arisz, L; Boeschoten, EW; Krediet, RT; Kuijper, EJ; Speelman, P; Struijk, DG, 1990) |
| "For the treatment of spontaneous bacterial peritonitis (SBP), cefotaxime, ceftriaxone, and ciprofloxacin were used as first-line agents." | 5.69 | Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP. ( Baik, SK; Han, KH; Heo, J; Heo, NY; Jung, YK; Kang, SH; Kim, BI; Kim, HS; Kim, MY; Kim, TH; Kim, YS; Park, JY; Park, SY; Seo, YS; Sohn, JH; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2023) |
| "Bacterial peritonitis is a well-recognized complication of chronic ambulatory peritoneal dialysis (CAPD) in patients with end-stage renal failure." | 5.33 | Ciprofloxacin treatment of bacterial peritonitis associated with chronic ambulatory peritoneal dialysis caused by Neisseria cinerea. ( Anijeet, H; Corkill, JE; Parry, CM; Saxena, R; Taegtmeyer, M, 2006) |
| "For the prevention of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites, norfloxacin 400 mg per day is recommended as a standard regimen." | 5.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "To compare an intravenous-oral step-down schedule with ciprofloxacin (switch therapy) to intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis, and to evaluate the impact of terlipressin and albumin in the treatment of type 1 hepatorenal syndrome on mortality." | 5.12 | Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. ( Angeli, P; Antona, C; Brollo, L; Cillo, U; Craighero, R; Fasolato, S; Franchin, M; Gatta, A; Guarda, S; Merkel, C; Miola, E; Piccolo, F, 2006) |
| "To evaluate the absorption of oral ciprofloxacin within 24 hours of laparotomy for major elective surgery or peritonitis." | 5.08 | Bioavailability of oral ciprofloxacin in early postsurgical patients. ( Christou, N; Duffy, DR; Hackam, DJ; Khaliq, Y; Marshall, JC; Rotstein, OD; Vaughan, D, 1998) |
| "The aim of this prospective double-blind study was to evaluate the value of long-term antibiotic prophylaxis using ciprofloxacin for the prevention of spontaneous bacterial peritonitis (SBP) in 60 cirrhotic patients with low ascitic fluid protein levels (< 15 g/L)." | 5.08 | Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. ( Bacq, Y; Bohn, B; Cordier, L; Franza, A; Fratte, S; Kitmacher, P; Nousbaum, JB; Paris, JC; Rolachon, A; Stahl, JP, 1995) |
| "The present study compared oral versus intraperitoneal (ip) ciprofloxacin (ciproxin) as primary treatment of bacterial peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD) in a randomized, prospective trial." | 5.07 | A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. ( Chan, CY; Cheng, IK; Cheng, SW; Cheung, WC; Lo, WK; Ritchie, CW; Wong, WT, 1993) |
| "Fifty-one patients were included in a prospective, randomized comparison of oral ciprofloxacin and intraperitoneal vancomycin/gentamicin in the treatment of CAPD peritonitis." | 5.06 | A comparison between oral ciprofloxacin and intra-peritoneal vancomycin and gentamicin in the treatment of CAPD peritonitis. ( Barrett, A; Bennett-Jones, DN; Russell, GI, 1990) |
| "Ciprofloxacin was evaluated as single-agent therapy for the empirical treatment of patients presenting with CAPD peritonitis in an open, uncontrolled trial." | 5.06 | Intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD). ( Barton, I; King, A; Ludlam, HA; McMullin, C; Phillips, I; White, L, 1990) |
| "This report describes a prospective, randomized comparison of oral ciprofloxacin and intraperitoneal vancomycin/netilmicin in the treatment of 50 consecutive episodes of CAPD peritonitis in 35 patients." | 5.06 | A comparison between oral ciprofloxacin and intraperitoneal vancomycin and netilmicin in CAPD peritonitis. ( Bint, AJ; George, JC; Orr, KE; Stansfield, E; Tapson, JS; Ward, MK, 1990) |
| "In a prospective, randomized, controlled trial in 40 patients, intraperitoneal ciprofloxacin was shown to be as effective as the currently recommended regimen of intraperitoneal vancomycin and gentamicin for the treatment of CAPD peritonitis." | 5.06 | A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD). ( Fraise, AP; Friedland, JS; Iveson, TJ; Oliver, DO; Selkon, JB; Winearls, CG, 1990) |
| " For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal)." | 4.84 | [Bacterial infections in liver cirrhosis]. ( Farkas, A; Papp, M; Tornai, I; Udvardy, M, 2007) |
| "Among several regimes used in the oral treatment of continuous ambulatory peritoneal dialysis (CAPD)--related peritonitis, ciprofloxacin and ofloxacin showed the higher treatment efficacy, with an overall cure rate of 80% over a treatment duration of 10-16 days." | 4.81 | The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis. ( Oreopoulos, D; Passadakis, P, 2001) |
| " Indexing terms included peritoneal dialysis, pharmacokinetics, peritonitis, vancomycin, and fluoroquinolones." | 4.78 | Continuous ambulatory peritoneal dialysis: a review of its mechanics, advantages, complications, and areas of controversy. ( Bailie, GR; Eisele, G, 1992) |
| "To estimate the efficacy of ciprofloxacin in the treatment of pelvic peritonitis, a pharmacokinetic study was conducted in four Japanese subjects." | 3.72 | Pharmacokinetics of single-dose intravenous ciprofloxacin in blood and ascites of patients with pelvic peritonitis. ( Mikamo, H; Ninomiya, M; Tamaya, T, 2003) |
| "Using 6-monthly urine and dialysis clearance measurements, preperitonitis and postperitonitis RRF (mean of 24-hour urea and creatinine clearance) were determined for 70 peritonitis episodes treated with the aminoglycoside-based regimen (group A), 61 episodes treated without aminoglycosides (group B), and 74 control patients without peritonitis (group C)." | 3.72 | Empirical aminoglycosides for peritonitis do not affect residual renal function. ( Baker, RJ; Brown, EA; Clemenger, M; Senior, H, 2003) |
| "We present the results of a protocol of empiric monotherapy of continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis with ciprofloxacin (CPX), with a special emphasis on the evolution of our results after seven years of continued use of this drug." | 3.69 | Treatment of CAPD-related peritonitis with ciprofloxacin: results after seven years. ( Bouza, P; García Falcón, T; López Vázquez, M; Pérez Fontán, M; Rodríguez-Carmona, A; Tresancos, C; Valdés, F, 1996) |
| "This study was designed to retrospectively review the experience in this center with oral ciprofloxacin 500 mg bid and ip vancomycin 25 mg/L in the treatment of CAPD-related exit site infections and to determine the relationship between exit site infections and peritonitis." | 3.68 | Relationship between peritonitis and exit site infections in CAPD. ( Bailie, GR; Eisele, G; Lomaestro, B, 1992) |
| "Ciprofloxacin was used as empirical therapy for peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD) for 26 months, providing an opportunity to study the epidemiology of ciprofloxacin resistance amongst coagulase-negative staphylococci (CNS)." | 3.68 | The epidemiology of ciprofloxacin resistance in coagulase-negative staphylococci in CAPD patients. ( Cookson, BD; Dryden, MS; McCann, M; Phillips, I; Talsania, H, 1992) |
| "The activity of cefuroxime, ciprofloxacin and imipenem against 50 coagulase-negative staphylococci (CNS) strains isolated from patients with peritonitis while on continuous ambulatory peritoneal dialysis (CAPD) was examined." | 3.68 | In-vitro activity of imipenem, in comparison with cefuroxime and ciprofloxacin, against coagulase-negative staphylococci in broth and peritoneal dialysis fluid. ( Geary, I; Spencer, RC; Wilcox, MH, 1992) |
| "We present the long-term results of a protocol of empirical monotherapy of continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis with ciprofloxacin." | 3.68 | Treatment of peritonitis in CAPD with ciprofloxacin: long-term experience. ( Adeva, M; Fernández Rivera, C; García Falcón, T; Moncalián, J; Pérez Fontán, M; Rodríguez-Carmona, A; Rosales, M, 1993) |
| "Ciprofloxacin cannot be recommended for the treatment of intermittent peritoneal dialysis-related Gram-positive bacterial peritonitis." | 3.68 | Poor response to oral ciprofloxacin in the treatment of peritonitis in patients on intermittent peritoneal dialysis. ( Fong, IW; Johnson, MD; Waite, NM; Webster, NR, 1993) |
| "Ciprofloxacin at a dose of 25 mg/L of dialysate was administered intraperitoneally for five days as a single agent for the empirical treatment of CAPD peritonitis." | 3.68 | Low dose intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD). ( Dryden, MS; Phillips, I; Wing, AJ, 1991) |
| "Forty two patients with general peritonitis were treated with ciprofloxacin and combinations of various antimicrobial drugs." | 3.68 | [Ciprofloxacin and other antimicrobial drugs in the treatment of disseminated peritonitis]. ( Bush, V; Chugunov, AO; Gorskiĭ, VA; Korshumov, VM; Kriger, AG; Levanov, AV; Shurkalin, BK, 1992) |
| "The concentration of ciprofloxacin was assayed in plasma and peritoneal dialysate following intraperitoneal administration of the drug in the absence of bacterial peritonitis." | 3.67 | Pharmacokinetics of intraperitoneal ciprofloxacin in patients on CAPD. ( Coles, GA; Dharmasena, D; Roberts, DE; Williams, JD, 1989) |
| "Ciprofloxacin is active in vitro against most bacteria that cause peritonitis associated with peritoneal dialysis." | 3.67 | Effect of peritoneal dialysis fluid and pH on bactericidal activity of ciprofloxacin. ( Echols, RM; McCormick, EM, 1987) |
| " The aim was to investigate the efficacy of long-term administration of ciprofloxacin to prevent SBP." | 2.73 | Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. ( Abecasis, R; Cartier, M; Dominguez, N; Fassio, E; Guevara, M; Landeira, C; Levi, D; Longo, C; Lucero, R; Miguez, C; Muñoz, A; Romero, G; Terg, R, 2008) |
| " enteral dosing was equivalent to that after 400 mg b." | 2.69 | Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections. ( Bruining, HA; Buijk, SL; de Marie, S; Kluytmans, JA; Mouton, JW; van Vliet, A; VandenBergh, MF, 1998) |
| "Ciprofloxacin was given two hours after any phosphate binder or iron supplement." | 2.69 | Once-daily intraperitoneal cefazolin and oral ciprofloxacin as empiric therapy for the treatment of peritonitis. ( Finkelstein, F; Gorban-Brennan, N; Kliger, A; Troidle, L, 1999) |
| " The dosage was deduced from a pilot study and consisted of an intra-peritoneal loading dose during the first 24 hours." | 2.67 | Oral treatment of CAPD-peritonitis with ciprofloxacin. ( Arisz, L; Boeschoten, EW; Krediet, RT; Kuijper, EJ; Speelman, P; Struijk, DG, 1990) |
| "Ciprofloxacin/metronidazole was more cost-effective compared with piperacillin/tazobactam (2200 US dollars-3600 US dollars lower cost-effective ratios per patient) regardless of whether the patient had a diagnosis of appendicitis or whether a switch to an oral drug was permissible." | 2.42 | Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections. ( Madan, AK, 2004) |
| "Bacterial peritonitis is a key complication of Peritoneal Dialysis (PD) and a preventable cause of withdrawal from PD treatment." | 1.62 | A Case of ( Bieber, SD; Burgstahler, MS; Pfeiffer, DC, 2021) |
| "Ciprofloxacin was stable at refrigeration-temperature and body-temperature in all PDFs evaluated over the whole study period of 14 days and 24 hours, respectively." | 1.51 | Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. ( Burgmann, H; Ferth, A; Kussmann, M; Obermüller, M; Pichler, P; Poeppl, W; Reznicek, G; Wiesholzer, M; Zeitlinger, M, 2019) |
| "Sepsis is a life-threatening disease resulted from a dysregulated host immune response to bacterial infections, continuing to cause high morbidity and mortality worldwide." | 1.48 | Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management. ( Gao, J; Wang, Z; Zhang, CY, 2018) |
| "The aac(6')-Ib-cr gene, in spite of producing low-level resistance by itself, plays a relevant role in acquisition of a clinical level of ciprofloxacin and norfloxacin resistance, when combined with three or four chromosomal mutations, both in vitro and in vivo." | 1.43 | Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli. ( Díaz-De-Alba, P; Docobo-Perez, F; Machuca, J; Ortiz, M; Pascual, Á; Recacha, E; Rodríguez-Martínez, JM, 2016) |
| "He was diagnosed with necrotizing fasciitis and later developed peritonitis after receiving a laceration from an aquatic injury suffered during the flood disaster of 2011." | 1.42 | A Report of Peritonitis from Aeromonas sobria in a Peritoneal Dialysis (PD) Patient with Necrotizing Fasciitis. ( Changsirikulchai, S; Janma, J; Linasmita, P, 2015) |
| " In combination with non-toxic dosage of Rh2, the susceptibilities of S." | 1.40 | Non-antibiotic agent ginsenoside 20(S)-Rh2 enhanced the antibacterial effects of ciprofloxacin in vitro and in vivo as a potential NorA inhibitor. ( Chen, Q; He, J; Liu, J; Lu, M; Sun, X; Sun, Y; Wang, G; Wang, Y; Zhang, J; Zhang, X; Zhou, F, 2014) |
| "Peritonitis is a major cause of morbidity in continuous ambulatory peritoneal dialysis (CAPD)." | 1.36 | Quinolone-resistant Aeromonas hydrophila peritonitis in a CAPD patient. ( Barut, HS; Sahin, I, 2010) |
| "Bacterial peritonitis is a well-recognized complication of chronic ambulatory peritoneal dialysis (CAPD) in patients with end-stage renal failure." | 1.33 | Ciprofloxacin treatment of bacterial peritonitis associated with chronic ambulatory peritoneal dialysis caused by Neisseria cinerea. ( Anijeet, H; Corkill, JE; Parry, CM; Saxena, R; Taegtmeyer, M, 2006) |
| "Peritonitis is a major complication of peritoneal dialysis (PD)." | 1.33 | Mycobacterium simiae: a previously undescribed pathogen in peritoneal dialysis peritonitis. ( Jeyaratnam, D; Keenan, N; Sheerin, NS, 2005) |
| "metronidazole (MTR) was compared with i." | 1.32 | Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment ( Asimakopoulos, C; Bassaris, H; Harlaftis, N; Karravias, D; Kolaras, P; Nikolaidis, P; Skoutelis, A; Starakis, I, 2003) |
| "stutszeri (1), and unidentified (1)." | 1.29 | Treatment and prevention of relapses of CAPD Pseudomonas peritonitis. ( Eftimimiadou, A; Kaliengidou, M; Kartali, S; Panagoutsos, S; Papazoglou, D; Pasadakis, P; Thodis, E; Vargemezis, V, 1993) |
| "Ciprofloxacin is an effective drug for initial treatment of SBP/CNNA." | 1.29 | Frequency, microbial spectrum and outcome of spontaneous bacterial peritonitis in north India. ( Ayyagari, A; Ghoshal, UC; Naik, SR; Puri, AS; Puri, J; Saraswat, VA; Sharma, BC, 1996) |
| "Ciprofloxacin was significantly less active in dialysate than in Iso-Sensitest broth (IB)." | 1.28 | Susceptibility testing of bacteria recovered from patients with peritonitis complicating continuous ambulatory peritoneal dialysis. ( Hopkins, P; Johnston, L; Ludlam, H, 1992) |
| " The present work uses an open, two-compartment pharmacokinetic model reversibly linked with the compartment representing the peritoneal cavity and an analog-hybrid computer to simulate drug levels in sampled and unsampled compartments under conditions of various routes of administration (IV, IP and sequential IV, IP and PO) and different clinical status (presence and absence of peritonitis)." | 1.28 | Computer simulation of ciprofloxacin pharmacokinetics in patients on CAPD. ( Bren, AF; Drinovec, J; Karba, R; Mrhar, A; Primozic, S; Varl, J; Zozjek, F, 1990) |
| "Peritonitis is the major complication of continuous ambulatory peritoneal dialysis (CAPD) and is caused predominantly by coagulase-negative staphylococci (CNS)." | 1.28 | Continuous ambulatory peritoneal dialysis (CAPD) peritonitis: the effect of antibiotic on the adherence of coagulase-negative staphylococci to silicone rubber catheter material. ( Edwards, R; Filik, R; Finch, RG; Wilcox, MH, 1989) |
| " This risk may depend on the dosing schedule and may be reduced by combined therapy." | 1.27 | Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. ( Auckenthaler, R; Michéa-Hamzehpour, M; Pechère, JC; Regamey, P, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (9.35) | 18.7374 |
| 1990's | 47 (43.93) | 18.2507 |
| 2000's | 21 (19.63) | 29.6817 |
| 2010's | 26 (24.30) | 24.3611 |
| 2020's | 3 (2.80) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z | 1 |
| Teng, D | 1 |
| Mao, R | 1 |
| Wang, X | 2 |
| Hao, Y | 1 |
| Wang, J | 1 |
| Yim, HJ | 2 |
| Kim, TH | 1 |
| Suh, SJ | 2 |
| Yim, SY | 2 |
| Jung, YK | 2 |
| Seo, YS | 2 |
| Kang, SH | 1 |
| Kim, MY | 1 |
| Baik, SK | 1 |
| Kim, HS | 2 |
| Kim, YS | 2 |
| Park, SY | 2 |
| Kim, BI | 2 |
| Park, JY | 1 |
| Heo, J | 1 |
| Sohn, JH | 1 |
| Heo, NY | 1 |
| Han, KH | 1 |
| Um, SH | 2 |
| Badal, BD | 1 |
| Silvey, S | 1 |
| Dragilev, L | 1 |
| O'Leary, JG | 1 |
| Morgan, TR | 1 |
| Cheung, R | 1 |
| Patel, A | 1 |
| Rogal, S | 1 |
| Patton, H | 1 |
| Nobbe, A | 1 |
| Jakab, SS | 1 |
| Liu, J | 2 |
| Patel, N | 1 |
| Bajaj, JS | 1 |
| Burgstahler, MS | 1 |
| Bieber, SD | 1 |
| Pfeiffer, DC | 1 |
| Mo, S | 1 |
| Bendtsen, F | 1 |
| Wiese, SS | 1 |
| Kimer, N | 1 |
| Lee, YR | 1 |
| Jang, JY | 1 |
| Zhang, CY | 1 |
| Gao, J | 1 |
| Wang, Z | 1 |
| Haugan, MS | 1 |
| Løbner-Olesen, A | 1 |
| Frimodt-Møller, N | 1 |
| Carvalho, TJ | 1 |
| Branco, PQ | 1 |
| Martins, AR | 1 |
| Gaspar, A | 1 |
| Lundin, MS | 1 |
| Chintu, MR | 1 |
| Kussmann, M | 1 |
| Ferth, A | 1 |
| Obermüller, M | 1 |
| Pichler, P | 1 |
| Zeitlinger, M | 1 |
| Wiesholzer, M | 1 |
| Burgmann, H | 1 |
| Poeppl, W | 1 |
| Reznicek, G | 1 |
| Wang, W | 2 |
| Yang, J | 1 |
| Liu, C | 1 |
| Song, P | 1 |
| Xu, H | 1 |
| Xia, X | 1 |
| Vinnitskaia, EV | 1 |
| Drozdov, VN | 1 |
| Petyrakov, AV | 1 |
| Sil'vestrova, SIu | 1 |
| Brezgin, AG | 1 |
| Gabaldon, D | 1 |
| Wiggins, B | 1 |
| Tzamaloukas, AH | 1 |
| Bert, F | 1 |
| Larroque, B | 1 |
| Dondero, F | 1 |
| Durand, F | 1 |
| Paugam-Burtz, C | 1 |
| Belghiti, J | 1 |
| Moreau, R | 1 |
| Nicolas-Chanoine, MH | 1 |
| Jain, V | 1 |
| Shukla, P | 1 |
| Pal, R | 1 |
| Mishra, PR | 1 |
| Yusuf, E | 1 |
| Wybo, I | 1 |
| François, K | 1 |
| Pipeleers, L | 1 |
| Echahidi, F | 1 |
| Covens, L | 1 |
| Piérard, D | 1 |
| Zhang, J | 1 |
| Sun, Y | 1 |
| Wang, Y | 1 |
| Lu, M | 1 |
| He, J | 1 |
| Chen, Q | 1 |
| Zhang, X | 1 |
| Zhou, F | 1 |
| Wang, G | 1 |
| Sun, X | 1 |
| Kim, SW | 1 |
| Kim, JE | 1 |
| Hong, YA | 1 |
| Ko, GJ | 1 |
| Pyo, HJ | 1 |
| Kwon, YJ | 1 |
| Tamm, TI | 2 |
| Nepomnyashchiy, VV | 1 |
| Shakalova, EA | 1 |
| Dvornik, IA | 1 |
| Azzam, O | 1 |
| Crowe, A | 1 |
| Sajiv, C | 1 |
| Pawar, B | 1 |
| Janma, J | 1 |
| Linasmita, P | 1 |
| Changsirikulchai, S | 1 |
| Machuca, J | 1 |
| Ortiz, M | 1 |
| Recacha, E | 1 |
| Díaz-De-Alba, P | 1 |
| Docobo-Perez, F | 1 |
| Rodríguez-Martínez, JM | 1 |
| Pascual, Á | 1 |
| Lutz, P | 1 |
| Nischalke, HD | 1 |
| Krämer, B | 1 |
| Goeser, F | 1 |
| Kaczmarek, DJ | 1 |
| Schlabe, S | 1 |
| Parcina, M | 1 |
| Nattermann, J | 1 |
| Hoerauf, A | 1 |
| Strassburg, CP | 1 |
| Spengler, U | 1 |
| Paladino, JA | 1 |
| Gilliland-Johnson, KK | 1 |
| Adelman, MH | 1 |
| Cohn, SM | 1 |
| Miklaszewska, M | 1 |
| Klepacka, J | 1 |
| Drozdz, D | 1 |
| Zachwieja, K | 1 |
| Pietrzyk, JA | 1 |
| Kadłubowski, M | 1 |
| Hryniewicz, W | 1 |
| Monescillo Francia, A | 1 |
| Sahin, I | 1 |
| Barut, HS | 1 |
| Quintela Obregón, E | 1 |
| Palomar Fontanet, R | 1 |
| Salas, C | 1 |
| Rodrigo Calabia, E | 1 |
| Arias Rodríguez, M | 1 |
| Senzolo, M | 1 |
| Nadal, E | 1 |
| Cholongitas, E | 1 |
| Burroughs, AK | 1 |
| Reuken, PA | 1 |
| Pletz, MW | 1 |
| Baier, M | 1 |
| Pfister, W | 1 |
| Stallmach, A | 1 |
| Bruns, T | 1 |
| Tsai, SF | 1 |
| Chen, CH | 1 |
| Shu, KH | 1 |
| Wu, MJ | 1 |
| Starakis, I | 1 |
| Karravias, D | 1 |
| Asimakopoulos, C | 1 |
| Kolaras, P | 1 |
| Nikolaidis, P | 1 |
| Harlaftis, N | 1 |
| Skoutelis, A | 1 |
| Bassaris, H | 1 |
| Baker, RJ | 1 |
| Senior, H | 1 |
| Clemenger, M | 1 |
| Brown, EA | 1 |
| Mikamo, H | 2 |
| Ninomiya, M | 1 |
| Tamaya, T | 2 |
| Hardman, SC | 1 |
| Carr, SJ | 1 |
| Swann, RA | 1 |
| Perera, S | 1 |
| Palasuntheram, C | 1 |
| Madan, AK | 1 |
| Keenan, N | 1 |
| Jeyaratnam, D | 1 |
| Sheerin, NS | 1 |
| Angeli, P | 1 |
| Guarda, S | 1 |
| Fasolato, S | 1 |
| Miola, E | 1 |
| Craighero, R | 1 |
| Piccolo, F | 1 |
| Antona, C | 1 |
| Brollo, L | 1 |
| Franchin, M | 1 |
| Cillo, U | 1 |
| Merkel, C | 1 |
| Gatta, A | 1 |
| Taegtmeyer, M | 1 |
| Saxena, R | 1 |
| Corkill, JE | 1 |
| Anijeet, H | 1 |
| Parry, CM | 1 |
| Song, JY | 1 |
| Jung, SJ | 1 |
| Park, CW | 1 |
| Sohn, JW | 1 |
| Kim, WJ | 1 |
| Kim, MJ | 1 |
| Cheong, HJ | 1 |
| Shinagawa, N | 1 |
| Yura, J | 1 |
| Takeyama, H | 1 |
| Taniguchi, M | 1 |
| Papp, M | 1 |
| Farkas, A | 1 |
| Udvardy, M | 1 |
| Tornai, I | 1 |
| Ito, K | 1 |
| Izumi, K | 1 |
| Tanaka, K | 1 |
| Watanabe, K | 1 |
| Terg, R | 3 |
| Fassio, E | 2 |
| Guevara, M | 2 |
| Cartier, M | 1 |
| Longo, C | 1 |
| Lucero, R | 1 |
| Landeira, C | 1 |
| Romero, G | 1 |
| Dominguez, N | 1 |
| Muñoz, A | 1 |
| Levi, D | 2 |
| Miguez, C | 1 |
| Abecasis, R | 2 |
| Brunel, AS | 1 |
| Fraisse, T | 1 |
| Lechiche, C | 1 |
| Sotto, A | 1 |
| Laporte, S | 1 |
| Rolachon, A | 1 |
| Cordier, L | 1 |
| Bacq, Y | 1 |
| Nousbaum, JB | 1 |
| Franza, A | 1 |
| Paris, JC | 1 |
| Fratte, S | 1 |
| Bohn, B | 1 |
| Kitmacher, P | 1 |
| Stahl, JP | 1 |
| Burnett, RJ | 1 |
| Haverstock, DC | 1 |
| Dellinger, EP | 1 |
| Reinhart, HH | 1 |
| Bohnen, JM | 1 |
| Rotstein, OD | 2 |
| Vogel, SB | 1 |
| Solomkin, JS | 1 |
| Datsenko, BM | 1 |
| Usberti, M | 1 |
| Gazzotti, RM | 1 |
| Mileti, M | 1 |
| Brazzoli, A | 1 |
| Zucca, F | 1 |
| Depetri, G | 1 |
| Braga, B | 1 |
| Losio, R | 1 |
| Barretti, P | 2 |
| Bignardi, JH | 1 |
| Soares, VA | 1 |
| Pasadakis, P | 1 |
| Thodis, E | 1 |
| Eftimimiadou, A | 1 |
| Panagoutsos, S | 1 |
| Papazoglou, D | 1 |
| Kaliengidou, M | 1 |
| Kartali, S | 1 |
| Vargemezis, V | 1 |
| Pérez Fontán, M | 2 |
| Rosales, M | 2 |
| Rodríguez-Carmona, A | 2 |
| García Falcón, T | 2 |
| Adeva, M | 1 |
| Fernández Rivera, C | 1 |
| Moncalián, J | 2 |
| Cheng, IK | 1 |
| Chan, CY | 1 |
| Wong, WT | 1 |
| Cheng, SW | 1 |
| Ritchie, CW | 1 |
| Cheung, WC | 1 |
| Lo, WK | 1 |
| Waite, NM | 1 |
| Johnson, MD | 1 |
| Webster, NR | 1 |
| Fong, IW | 1 |
| Nye, KJ | 1 |
| Gibson, SP | 1 |
| Nwosu, AC | 1 |
| Manji, MR | 1 |
| Robinson, BH | 1 |
| Hawkins, JB | 1 |
| Levy, MJ | 1 |
| DiPalma, JA | 1 |
| Riley, UB | 1 |
| Bignardi, G | 1 |
| Goldberg, L | 1 |
| Johnson, AP | 1 |
| Holmes, B | 1 |
| Zacherle, BJ | 1 |
| Bouza, P | 1 |
| López Vázquez, M | 1 |
| Tresancos, C | 1 |
| Valdés, F | 2 |
| Puri, AS | 1 |
| Puri, J | 1 |
| Ghoshal, UC | 1 |
| Sharma, BC | 1 |
| Saraswat, VA | 1 |
| Ayyagari, A | 1 |
| Naik, SR | 1 |
| Leblanc, M | 1 |
| Goffin, E | 1 |
| Pouthier, D | 1 |
| Vandercam, B | 1 |
| Gigi, J | 1 |
| van Ypersele de Strihou, C | 1 |
| de Marie, S | 1 |
| VandenBergh, MF | 1 |
| Buijk, SL | 1 |
| Bruining, HA | 1 |
| van Vliet, A | 1 |
| Kluytmans, JA | 1 |
| Mouton, JW | 1 |
| Llano, K | 1 |
| Cobas, SM | 1 |
| Brotto, C | 1 |
| Barrios, A | 1 |
| Wasen, W | 1 |
| Bartellini, MA | 1 |
| Hackam, DJ | 1 |
| Christou, N | 1 |
| Khaliq, Y | 1 |
| Duffy, DR | 1 |
| Vaughan, D | 1 |
| Marshall, JC | 1 |
| McConkey, SJ | 1 |
| McCarthy, ND | 1 |
| Keane, CT | 1 |
| Montelli, A | 1 |
| Caramori, J | 1 |
| Troidle, L | 1 |
| Gorban-Brennan, N | 1 |
| Kliger, A | 1 |
| Finkelstein, F | 1 |
| Cobas, S | 1 |
| Landeira, G | 1 |
| Ríos, B | 1 |
| Vasen, W | 1 |
| Ríos, H | 1 |
| Duch, JM | 1 |
| Yee, J | 1 |
| Passadakis, P | 1 |
| Oreopoulos, D | 1 |
| Levanov, AV | 1 |
| Bush, V | 1 |
| Shurkalin, BK | 1 |
| Kriger, AG | 1 |
| Gorskiĭ, VA | 1 |
| Chugunov, AO | 1 |
| Korshumov, VM | 1 |
| Eisele, G | 2 |
| Bailie, GR | 2 |
| Lomaestro, B | 1 |
| Froidefond, S | 1 |
| Saivin, S | 1 |
| Lemozy, J | 1 |
| Marchou, B | 1 |
| Auvergnat, JC | 1 |
| Dabernat, H | 1 |
| Dryden, MS | 3 |
| Talsania, H | 1 |
| McCann, M | 1 |
| Cookson, BD | 1 |
| Phillips, I | 5 |
| Ludlam, H | 3 |
| Johnston, L | 1 |
| Hopkins, P | 1 |
| Pylypchuk, GB | 1 |
| Conly, J | 1 |
| Kappel, JE | 1 |
| Stein, K | 1 |
| Rennie, R | 1 |
| Wilcox, MH | 3 |
| Geary, I | 1 |
| Spencer, RC | 1 |
| Wing, AJ | 1 |
| Ludlam, HA | 2 |
| Taber, TE | 1 |
| Hegeman, TF | 1 |
| York, SM | 1 |
| Kinney, RA | 1 |
| Webb, DH | 1 |
| Pérez-Fontán, M | 1 |
| Fernández, F | 1 |
| Fernández-Rivera, C | 1 |
| Alonso, A | 1 |
| Boeschoten, EW | 1 |
| Kuijper, EJ | 1 |
| Speelman, P | 1 |
| Struijk, DG | 1 |
| Krediet, RT | 1 |
| Arisz, L | 1 |
| Janknegt, R | 1 |
| Finch, RG | 2 |
| Barton, I | 3 |
| White, L | 1 |
| McMullin, C | 1 |
| King, A | 1 |
| Phillips, G | 2 |
| Fleming, LW | 3 |
| Stewart, WK | 3 |
| Dryden, M | 1 |
| Tapson, JS | 1 |
| Orr, KE | 1 |
| George, JC | 1 |
| Stansfield, E | 1 |
| Bint, AJ | 1 |
| Ward, MK | 1 |
| Bennett-Jones, DN | 1 |
| Russell, GI | 1 |
| Barrett, A | 1 |
| Friedland, JS | 1 |
| Iveson, TJ | 1 |
| Fraise, AP | 1 |
| Winearls, CG | 1 |
| Selkon, JB | 1 |
| Oliver, DO | 1 |
| Scott, AC | 2 |
| Mrhar, A | 1 |
| Karba, R | 1 |
| Drinovec, J | 1 |
| Primozic, S | 1 |
| Varl, J | 1 |
| Bren, AF | 1 |
| Zozjek, F | 1 |
| Edwards, R | 1 |
| Filik, R | 1 |
| Dharmasena, D | 1 |
| Roberts, DE | 1 |
| Coles, GA | 1 |
| Williams, JD | 1 |
| Lahnborg, G | 1 |
| Nord, CE | 1 |
| Guay, D | 1 |
| Klicker, R | 1 |
| Pence, T | 1 |
| Peterson, P | 1 |
| Michéa-Hamzehpour, M | 1 |
| Auckenthaler, R | 1 |
| Regamey, P | 1 |
| Pechère, JC | 1 |
| Grave, W | 1 |
| Sturm, AW | 1 |
| McCormick, EM | 1 |
| Echols, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Terlipressin Given As I.V. Boluses Vs Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome (Hrs): Preliminary Results Of A Randomized Controlled Clinical Study.[NCT00742690] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2005-05-31 | Recruiting | ||
| Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis: an Open, Randomized, Controlled Clinical Trial[NCT01455246] | Phase 2/Phase 3 | 32 participants (Actual) | Interventional | 2010-10-31 | Terminated (stopped due to Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group.) | ||
| Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients[NCT01542801] | Phase 4 | 124 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for ciprofloxacin and Primary Peritonitis
| Article | Year |
|---|---|
Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis: a network meta-analysis.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Humans; Network Meta-Analysis; Norfloxac | 2019 |
[Spontaneous bacterial peritonitis in liver cirrhosis: optimization issues of prevention and treatment].
Topics: Anti-Infective Agents; Ascitic Fluid; Bacterial Infections; Ciprofloxacin; Female; Humans; Liver Cir | 2012 |
Peritonitis caused by Roseomonas in a patient undergoing automated peritoneal dialysis: case report and literature review.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Female; Gentamicins; Gram-Negative Bacterial Infections; | 2012 |
Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections.
Topics: Abdominal Abscess; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Gram-Negative Ba | 2004 |
[Bacterial infections in liver cirrhosis].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites; | 2007 |
The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis.
Topics: Administration, Oral; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Humans; Oflo | 2001 |
Continuous ambulatory peritoneal dialysis: a review of its mechanics, advantages, complications, and areas of controversy.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Peritoneal Dialysis, Continuous | 1992 |
CAPD peritonitis and fluoroquinolones: a review.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Ofloxacin; Pefloxacin; Peritoneal Dialysis, Continuous | 1991 |
23 trials available for ciprofloxacin and Primary Peritonitis
| Article | Year |
|---|---|
Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; Cefotaxime; Ceftriaxo | 2023 |
Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; Ciprofloxacin; Disease-Free Survi | 2018 |
Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.
Topics: Abdominal Abscess; Adult; Aged; Anti-Bacterial Agents; Appendicitis; Ciprofloxacin; Cost-Benefit Ana | 2008 |
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.
Topics: Administration, Oral; Albumins; Anti-Bacterial Agents; Antihypertensive Agents; Ceftazidime; Ciprofl | 2006 |
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.
Topics: Administration, Oral; Albumins; Anti-Bacterial Agents; Antihypertensive Agents; Ceftazidime; Ciprofl | 2006 |
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.
Topics: Administration, Oral; Albumins; Anti-Bacterial Agents; Antihypertensive Agents; Ceftazidime; Ciprofl | 2006 |
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.
Topics: Administration, Oral; Albumins; Anti-Bacterial Agents; Antihypertensive Agents; Ceftazidime; Ciprofl | 2006 |
[Effectiveness of switch therapy for peritonitis].
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Clindamycin; Drug Administr | 2007 |
Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study.
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Middle Aged; Perito | 2008 |
Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial.
Topics: Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Ascites; Bacterial Infections; Ciproflox | 1995 |
Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial.
Topics: Abscess; Adult; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Double-Blind Method; Drug Resistan | 1995 |
[Cifran -- clinical effectiveness in the prevention and treatment of infection].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Appendicitis; Bacterial Infections; Cholecyst | 1994 |
A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis.
Topics: Administration, Oral; Ciprofloxacin; Humans; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis | 1993 |
New options for spontaneous bacterial prophylaxis: costly or cost effective?
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Humans; Peritonitis | 1996 |
Oral ciprofloxacin for the first-phase treatment of peritonitis associated with continuous ambulatory peritoneal dialysis.
Topics: Administration, Oral; Anti-Infective Agents; Ascitic Fluid; Ciprofloxacin; Follow-Up Studies; Humans | 1996 |
Oral ciprofloxacin to treat bacterial peritonitis associated with peritoneal dialysis.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Com | 1997 |
Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections.
Topics: Adult; Aged; Anti-Infective Agents; Biological Availability; Ciprofloxacin; Creatinine; Critical Car | 1998 |
Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, | 1998 |
Bioavailability of oral ciprofloxacin in early postsurgical patients.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Biological Availability; Ciprofloxacin; Elective | 1998 |
Once-daily intraperitoneal cefazolin and oral ciprofloxacin as empiric therapy for the treatment of peritonitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cefazolin; Ciprofloxacin; Drug Administration | 1999 |
Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study.
Topics: Administration, Oral; Analysis of Variance; Anti-Infective Agents; Ascitic Fluid; Ciprofloxacin; Cre | 2000 |
Oral treatment of CAPD-peritonitis with ciprofloxacin.
Topics: Administration, Oral; Ciprofloxacin; Drug Evaluation; Humans; Peritoneal Dialysis, Continuous Ambula | 1990 |
Intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD).
Topics: Adult; Ciprofloxacin; Clinical Trials as Topic; Dialysis Solutions; Humans; Microbial Sensitivity Te | 1990 |
A comparison between oral ciprofloxacin and intraperitoneal vancomycin and netilmicin in CAPD peritonitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Female; Humans; Injections, Int | 1990 |
A comparison between oral ciprofloxacin and intra-peritoneal vancomycin and gentamicin in the treatment of CAPD peritonitis.
Topics: Administration, Oral; Adult; Ciprofloxacin; Gentamicins; Humans; Injections, Intraperitoneal; Perito | 1990 |
A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD).
Topics: Adult; Aged; Ciprofloxacin; Female; Gentamicins; Humans; Injections, Intraperitoneal; Male; Middle A | 1990 |
76 other studies available for ciprofloxacin and Primary Peritonitis
| Article | Year |
|---|---|
Improved Antibacterial Activity of the Marine Peptide N6 against Intracellular Salmonella Typhimurium by Conjugating with the Cell-Penetrating Peptide Tat
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cell-Penetrating Peptides; Female; | 2018 |
Primary prophylaxis for spontaneous bacterial peritonitis is linked to antibiotic resistance in the Veterans Health Administration.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Drug Resistance, Bacterial; Escherichi | 2023 |
A Case of
Topics: Aged; Ciprofloxacin; Humans; Male; Methylobacteriaceae; Peritoneal Dialysis; Peritonitis; Renal Dial | 2021 |
Low ascitic fluid total protein levels is not associated to the development of spontaneous bacterial peritonitis in a cohort of 274 patients with cirrhosis.
Topics: Anti-Bacterial Agents; Ascites; Ascitic Fluid; Bacterial Infections; Biomarkers; Ciprofloxacin; Denm | 2018 |
Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management.
Topics: Amides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Proteins; | 2018 |
Comparative Activity of Ceftriaxone, Ciprofloxacin, and Gentamicin as a Function of Bacterial Growth Rate Probed by Escherichia coli Chromosome Replication in the Mouse Peritonitis Model.
Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Disease Models, Animal; Escherichia coli | 2019 |
Topics: Aged; Anti-Bacterial Agents; Catheter-Related Infections; Ceftazidime; Chryseobacterium; Ciprofloxac | 2018 |
Biceps tendon rupture associated with ciprofloxacin use for spontaneous bacterial peritonitis prophylaxis.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Emergency | 2019 |
Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions.
Topics: Anti-Bacterial Agents; Biocompatible Materials; Chromatography, High Pressure Liquid; Ciprofloxacin; | 2019 |
Pseudomonas luteola peritonitis with favorable outcome in continuous peritoneal dialysis.
Topics: Aged; Anti-Bacterial Agents; Catheters, Indwelling; Ceftazidime; Ciprofloxacin; Diabetic Nephropathi | 2013 |
Risk factors associated with preoperative fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in liver transplant recipients.
Topics: Adult; Amikacin; beta-Lactamases; beta-Lactams; Cefoxitin; Ciprofloxacin; Drug Resistance, Bacterial | 2014 |
Cationic nanoemulsions bearing ciprofloxacin surf-plexes enhances its therapeutic efficacy in conditions of E. coli induced peritonitis and sepsis.
Topics: Animals; Anti-Bacterial Agents; Cations; Chitosan; Ciprofloxacin; Deoxycholic Acid; Drug Carriers; E | 2014 |
Microbacterium spp. as a cause of peritoneal-dialysis-related peritonitis in two patients.
Topics: Acinetobacter; Actinobacteria; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Ciprofloxac | 2016 |
Non-antibiotic agent ginsenoside 20(S)-Rh2 enhanced the antibacterial effects of ciprofloxacin in vitro and in vivo as a potential NorA inhibitor.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Drug Synergism; Ginsenosides; Mal | 2014 |
Raoultella planticola peritonitis in a patient on continuous ambulatory peritoneal dialysis.
Topics: Aged; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Enterobacteriaceae; Enterobacteriaceae Infe | 2015 |
[Prophylaxis of purulent complications in mechanical ileus].
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Biological Transport; Cephalosporins; Ciprofloxacin; Dis | 2015 |
Rhodococcus equi peritonitis in continuous ambulatory peritoneal dialysis: a first in Australia.
Topics: Actinomycetales Infections; Adult; Anti-Infective Agents; Australia; Azithromycin; Ciprofloxacin; Dr | 2015 |
A Report of Peritonitis from Aeromonas sobria in a Peritoneal Dialysis (PD) Patient with Necrotizing Fasciitis.
Topics: Aeromonas; Aged; Anti-Bacterial Agents; Ciprofloxacin; Diagnosis, Differential; Fasciitis, Necrotizi | 2015 |
Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Chromosomes, Bacterial; Ciprofloxacin; Disease Models, Animal; Esche | 2016 |
Antibiotic resistance in healthcare-related and nosocomial spontaneous bacterial peritonitis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Ciprofloxacin; Cross Infection; Drug | 2017 |
[Peritonitis in the course of peritoneal dialisis caused by Haemophilus influenzae with BLNAR phenotype].
Topics: Adolescent; Ampicillin Resistance; Ascitic Fluid; Ciprofloxacin; Haemophilus Infections; Haemophilus | 2009 |
[Spontaneous bacterial peritonitis].
Topics: Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Humans; Ofloxacin; Peritonitis; Primary Prevention | 2009 |
Quinolone-resistant Aeromonas hydrophila peritonitis in a CAPD patient.
Topics: Adult; Aeromonas hydrophila; Anti-Infective Agents; Ceftazidime; Ciprofloxacin; Drug Resistance, Bac | 2010 |
[Ochrobactrum anthropi and polymicrobial peritonitis in peritoneal dialysis: a resistance predictor].
Topics: Anti-Bacterial Agents; Antifungal Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug | 2010 |
Is hydrophobia necessary for the hepatologist prescribing nonselective beta-blockers in cirrhosis?
Topics: Adrenergic beta-Antagonists; Aged; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, | 2011 |
Emergence of spontaneous bacterial peritonitis due to enterococci - risk factors and outcome in a 12-year retrospective study.
Topics: Aged; Analysis of Variance; Anti-Infective Agents; Ascitic Fluid; Cephalosporins; Ciprofloxacin; Ent | 2012 |
Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment
Topics: Abdominal Abscess; Adult; Aged; Bacterial Infections; Ceftriaxone; Ciprofloxacin; Double-Blind Metho | 2003 |
Empirical aminoglycosides for peritonitis do not affect residual renal function.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefazolin; Ciprofloxaci | 2003 |
Pharmacokinetics of single-dose intravenous ciprofloxacin in blood and ascites of patients with pelvic peritonitis.
Topics: Anti-Infective Agents; Ascitic Fluid; Ciprofloxacin; Escherichia coli; Female; Genital Diseases, Fem | 2003 |
Peritoneal dialysis-related peritonitis with bacteraemia due to Erysipelothrix rhusiopathiae.
Topics: Anti-Infective Agents; Bacteremia; Ciprofloxacin; Erysipelothrix; Erysipelothrix Infections; Humans; | 2004 |
Chryseobacterium meningosepticum infections in a dialysis unit.
Topics: Chryseobacterium; Ciprofloxacin; Cross Infection; Equipment Contamination; Flavobacteriaceae Infecti | 2004 |
Mycobacterium simiae: a previously undescribed pathogen in peritoneal dialysis peritonitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Amikacin; Amoxicillin; Antiretroviral Therapy, Highly | 2005 |
Ciprofloxacin treatment of bacterial peritonitis associated with chronic ambulatory peritoneal dialysis caused by Neisseria cinerea.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Gentamicins; Humans; Kidney Failure, Chronic; Male; Nei | 2006 |
Prognostic significance of infection acquisition sites in spontaneous bacterial peritonitis: nosocomial versus community acquired.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Cefotaxime; Ciprofloxacin; Community-Acquired Inf | 2006 |
[Bilophila wadsworthia isolated from surgical specimens].
Topics: Anti-Bacterial Agents; beta-Lactams; Bilophila; Ciprofloxacin; Clindamycin; Digestive System Surgica | 2006 |
[A sexually transmitted peritonitis].
Topics: Ceftriaxone; Ciprofloxacin; Drug Therapy, Combination; Female; Gonorrhea; Humans; Middle Aged; Perit | 2008 |
Treatment of acute peritonitis by temporary discontinuation of dialysis and low doses of oral ciprofloxacin in patients on CAPD.
Topics: Acute Disease; Administration, Oral; Bacterial Infections; Cefazolin; Ciprofloxacin; Clinical Protoc | 1994 |
Successful treatment of peritonitis in IPD with oral fluoroquinolone.
Topics: Administration, Oral; Ciprofloxacin; Humans; Ofloxacin; Peritoneal Dialysis; Peritoneal Dialysis, Co | 1994 |
Treatment and prevention of relapses of CAPD Pseudomonas peritonitis.
Topics: Ceftazidime; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Male; Peritoneal Dialysis, Co | 1993 |
Treatment of peritonitis in CAPD with ciprofloxacin: long-term experience.
Topics: Ciprofloxacin; Humans; Microbial Sensitivity Tests; Peritoneal Dialysis, Continuous Ambulatory; Peri | 1993 |
Poor response to oral ciprofloxacin in the treatment of peritonitis in patients on intermittent peritoneal dialysis.
Topics: Acute Disease; Administration, Oral; Ciprofloxacin; Female; Humans; Male; Microbial Sensitivity Test | 1993 |
Single-dose intraperitoneal vancomycin and oral ciprofloxacin for the treatment of peritonitis in CAPD patients: preliminary report.
Topics: Administration, Oral; Ciprofloxacin; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; | 1993 |
Quinolone resistance in Oligella urethralis-associated chronic ambulatory peritoneal dialysis peritonitis.
Topics: Adult; Aged; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Huma | 1996 |
Treatment of CAPD-related peritonitis with ciprofloxacin: results after seven years.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Gram-Negative Bacterial Infections; Gram | 1996 |
Frequency, microbial spectrum and outcome of spontaneous bacterial peritonitis in north India.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Cohort Stu | 1996 |
Oral ciprofloxacin to treat bacterial peritonitis associated with peritoneal dialysis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Escherichia coli; Escherichia coli | 1997 |
Primary peritonitis due to nonenteric salmonellae.
Topics: Adolescent; Aged; Amoxicillin; Cefotaxime; Ciprofloxacin; Clavulanic Acid; Fatal Outcome; Humans; Ma | 1999 |
Monotherapy with oral ciprofloxacin to treat bacterial peritonitis associated with peritoneal dialysis.
Topics: Administration, Oral; Anti-Infective Agents; Ciprofloxacin; Humans; Peritoneal Dialysis; Peritonitis | 1999 |
National guideline for the management of pelvic infection and perihepatitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
Topics: Anti-Bacterial Agents; Cefoxitin; Ceftriaxone; Ciprofloxacin; Clindamycin; Contact Tracing; Female; | 1999 |
Successful use of recombinant tissue plasminogen activator in a patient with relapsing peritonitis.
Topics: Adult; Cefepime; Cephalosporins; Ciprofloxacin; Drug Therapy, Combination; Gentamicins; Humans; Inje | 2001 |
[Ciprofloxacin and other antimicrobial drugs in the treatment of disseminated peritonitis].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Drug Therapy, Combination; Humans; In | 1992 |
Relationship between peritonitis and exit site infections in CAPD.
Topics: Ciprofloxacin; Humans; Infections; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Recurren | 1992 |
[Resistance to antibiotic treatment produced in a model of experimental Pseudomonas aeruginosa peritonitis].
Topics: Amikacin; Animals; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; D | 1992 |
The epidemiology of ciprofloxacin resistance in coagulase-negative staphylococci in CAPD patients.
Topics: Air Microbiology; Carrier State; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Health | 1992 |
Susceptibility testing of bacteria recovered from patients with peritonitis complicating continuous ambulatory peritoneal dialysis.
Topics: Ciprofloxacin; Humans; Microbial Sensitivity Tests; Peritoneal Dialysis, Continuous Ambulatory; Peri | 1992 |
Sensitivity of CAPD/IPD peritonitis organisms to ciprofloxacin.
Topics: Ciprofloxacin; Humans; Microbial Sensitivity Tests; Peritoneal Dialysis; Peritoneal Dialysis, Contin | 1991 |
In-vitro activity of imipenem, in comparison with cefuroxime and ciprofloxacin, against coagulase-negative staphylococci in broth and peritoneal dialysis fluid.
Topics: Cefuroxime; Ciprofloxacin; Dialysis Solutions; Drug Resistance, Microbial; Humans; Imipenem; Microbi | 1992 |
Low dose intraperitoneal ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD).
Topics: Adolescent; Adult; Aged; Ciprofloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infu | 1991 |
Ciprofloxacin and CAPD peritonitis.
Topics: Ciprofloxacin; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Peritoneal Dialysis, | 1991 |
Treatment of Pseudomonas infections in peritoneal dialysis patients.
Topics: Ceftazidime; Ciprofloxacin; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Peritone | 1991 |
Ciprofloxacin in the treatment of gram-positive bacterial peritonitis in patients undergoing CAPD.
Topics: Administration, Oral; Ciprofloxacin; Gram-Positive Bacterial Infections; Humans; Injections, Intrape | 1991 |
Ciprofloxacin and CAPD peritonitis.
Topics: Ciprofloxacin; Coagulase; Drug Resistance, Microbial; Humans; Peritoneal Dialysis, Continuous Ambula | 1990 |
Pseudomonas paucimobilis peritonitis in a patient on CAPD successfully treated with ciprofloxacin and netilmicin.
Topics: Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Middle Aged; Netilmicin; Peritoneal Dialys | 1990 |
Short course ciprofloxacin therapy for CAPD peritonitis.
Topics: Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Humans; Kidney Failure, Chronic; Pe | 1990 |
Oral ciprofloxacin in the treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis.
Topics: Administration, Oral; Adult; Aged; Ciprofloxacin; Humans; Leukocyte Count; Middle Aged; Peritoneal D | 1990 |
Computer simulation of ciprofloxacin pharmacokinetics in patients on CAPD.
Topics: Administration, Oral; Adult; Aged; Ciprofloxacin; Computer Simulation; Drug Administration Schedule; | 1990 |
Continuous ambulatory peritoneal dialysis (CAPD) peritonitis: the effect of antibiotic on the adherence of coagulase-negative staphylococci to silicone rubber catheter material.
Topics: Bacterial Adhesion; Catheters, Indwelling; Cefuroxime; Ciprofloxacin; Humans; Peritoneal Dialysis, C | 1989 |
Treatment of CAPD peritonitis with oral ciprofloxacin.
Topics: Administration, Oral; Ciprofloxacin; Humans; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis | 1989 |
Intraperitoneal treatment of CAPD peritonitis with ciprofloxacin.
Topics: Bacteria; Ciprofloxacin; Costs and Cost Analysis; Humans; Peritoneal Dialysis, Continuous Ambulatory | 1989 |
Pharmacokinetics of intraperitoneal ciprofloxacin in patients on CAPD.
Topics: Ciprofloxacin; Humans; Infusions, Parenteral; Peritoneal Dialysis, Continuous Ambulatory; Peritoniti | 1989 |
Effect of ciprofloxacin compared to gentamicin in the treatment of experimental intraabdominal infections in rats.
Topics: Abdomen; Abscess; Animals; Bacterial Infections; Ciprofloxacin; Clindamycin; Drug Combinations; Gent | 1989 |
In vitro antistaphylococcal activity of teicoplanin and ciprofloxacin in peritoneal dialysis effluent.
Topics: Anti-Bacterial Agents; Ascitic Fluid; Cefazolin; Ciprofloxacin; Glycopeptides; Humans; Oxacillin; Pe | 1986 |
Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.
Topics: Animals; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Mice; Mice, I | 1987 |
Treatment of Pseudomonas aeruginosa peritonitis in a CAPD patient with ciprofloxacin.
Topics: Ciprofloxacin; Female; Humans; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; | 1988 |
Efficacy of ciprofloxacin in treatment of CAPD peritonitis.
Topics: Ciprofloxacin; Humans; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Pseudomonas Infectio | 1987 |
Effect of peritoneal dialysis fluid and pH on bactericidal activity of ciprofloxacin.
Topics: Anti-Bacterial Agents; Ascitic Fluid; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Synergism; | 1987 |